IdoAmitLab

What if we could turn the tumor’s deadliest tricks against it? New @Cancer_Cell: Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells. Led by @GalYagel, @D_Rimini & @MVLocquenghien (1/15) cell.com/cancer-cell/ab…

@VillarVesga @SciImmunology Amazing work Juan, Burkhard, Sarah and team!

Excited to share our new study out in @SciImmunology We show that Monocyte-derived Macrophages drive oxidative damage during neuroinflammation science.org/doi/10.1126/sc…

@bloodgenes @lvchosen1 @silvirouskin @Armstrong_dfci @CellPressNews @DanaFarberNews @DanaFarber @BroadMPG @broadinstitute @hhmi_science @BostonChildrens @GauravA_UK @guo_chunjie Congratulations Vijay and co. for this stimulating study!

🚨 Excited to share a new paper in Cell! Human genetics led us to HOTSCRAMBL, a HOXA-locus lncRNA that regulates 🩸#stemcell self-renewal and HOXA9 splicing, with implications for AML. Amazing work by @lvchosen1 with @silvirouskin, @Armstrong_dfci, and many more! cell.com/cell/fulltext/…

Beautiful work Marco and co. congratulations!

Fantastic new study by @Brown_lab1, @MiriamMerad and teams: mRNA vaccine potency comes from detargeting hepatocytes, not dendritic cell expression, avoiding PD1/PDL1-driven T cell suppression. A path to better, more effective therapies. nature.com/articles/s4158…

עידן חדש באמת. המחקר הזה הוא הישג גדול להדסה ולרפואה הישראלית, ומציב את ישראל בחזית העולמית של טיפולי CAR-T למחלות אוטואימוניות. שאפו גדול לפרופ’ חמוטל גור, פרופ’ פולינה סטפנסקי וד”ר שלמה אליאס על הובלה אמיצה וחדשנית של תחום עם פוטנציאל לשנות את חיי המטופלים מן היסוד.

#SCG2026 registration opens at 1 PM UK time on Thursday, 30 April. Spots are limited, and in previous years registration filled in less time than it takes to run a UMAP. Register here: conferences.weizmann.ac.il/SCG2026/

Beautiful work @garber_manuel and co. Immunology is magical! nature.com/articles/s4159…

@ZelzerLab 🤩🍜

Third year of celebrating Chinese New Year in the lab 🧧🐎
A slightly belated celebration this time, but no less festive Many thanks to Christina for bringing it all together, and to Eli for hosting Happy Year of the Horse 🐴✨

@OdedRechavi Technically, this may not require major changes and could even improve the process. Panel members can be stricter with unfunded proposals and use B scores to clearly flag uncompetitive applications. There is no rule limiting how many proposals can fall into the B category.

Announced by the ERC today (really bad news for science!!! It starts in Europe but will affect everybody) Because the REVIEWING LOAD is so bad, if your application fails you may need to wait mulitple years (>3?!?) until you can submit again! The ERC is the lifeline of the leading labs in Europe, so many research programs will be terminated (just no other sources to compensate). The letter from the ERC says “the only way is to reduce applications” (highlighted in the picture below) No!!! It's the wrong direction. Use AI to assist review. It’s not perfect (yet), but it allows more proposals to be evaluated, and it could support, not replace, human reviewers.

@AndrewFMalone @ucddublin @UCD_Research @UCD_Conway @WashUNephrology @svuh Beautiful study Andrew, a very elegant use of cell–cell interaction analysis!

I am happy to see this paper getting so much attention! I think this approach, modified from @IdoAmitLab ‘s amazing PICseq, is a useful tool to investigate the alloimmune response in human solid organ transplantation @ucddublin @UCD_Research @UCD_Conway @WashUNephrology @svuh

Congratulations Dr. Von Locquenghien @MVLocquenghien for successfully defending your PhD thesis! 🎉

Mimouna celebration at the AmitLab! 🤩🎉

@GallowayLabMIT @NatureBiotech @MITChemE @kochinstitute @MITdeptofBE @science_sneha @yunbeenbae @kaseyslove @DeonPloessl Congratulations Katie and co. beautiful work!

🤔How do you design a promoter for stable titration of expression? 💡Try programmable promoter editing with DIAL! 📰Now published at @NatureBiotech 🧵 [1/n] 🔗 below

@D_Rothschild_ Thank you Bup 🤩, as an alum, you are always welcome

@IdoAmitLab May you always have reasons to celebrate 🥂

Celebrating amazing discoveries, innovation, and the people who make it all possible. #Unstoppable

This is what real progress against cancer looks like: immunotherapy exploiting tumor vulnerabilities one after another. Now it’s time to extend that progress to many more tumor types!

Beautiful and important work from Aaron, colleagues, and the Adimab team. If we are still missing such a basic property of therapeutic antibodies, imagine how much of Ab mechanism of action we still do not fully understand, and how much more could be achieved if we did.

@Mayer46231196 @Cancer_Cell @GalYagel @D_Rimini @MVLocquenghien Thank you! 🙏🏻

@IdoAmitLab @Cancer_Cell @GalYagel @D_Rimini @MVLocquenghien This is very interesting. Congratulations

What if we could turn the tumor’s deadliest tricks against it? New @Cancer_Cell: Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells. Led by @GalYagel, @D_Rimini & @MVLocquenghien (1/15) cell.com/cancer-cell/ab…

@SabanLab This is absolutely beautiful 😻Congratulations Danny for pushing the limits of eye immunity!

We are excited to share that our team's paper is published in Immunity: "Resident tissue macrophages maintain intraocular pressure homeostasis." This work grew out of a collaboration between glaucoma clinician-scientist Katy Liu MD PhD, glaucoma physiologist W. Daniel Stamer PhD, and immunologist Daniel Saban PhD, bringing together clinical, physiological, and immunological expertise to tackle a long-standing question: does the immune system directly regulate intraocular pressure? The answer is yes. authors.elsevier.com/a/1mkeB3qNrV3V… #Glaucoma #Immunology #ResidentMacrophages #Ophthalmology #Immunity #CellPress cell.com/immunity/fullt…

@MiriYagelS1961 @cancercell @GalYagel @D_Rimini @Cancer_Cell Thank you Ima, Yagel power! 💪

@IdoAmitLab @cancercell @GalYagel @D_Rimini Congratulations @Cancer_Cell, what an excellent choice of a beautiful design for the March 2026 issue cover. Congratulations @IdoamitLab @GalYagel @D_Rimini, for being chosen by Cancer Cell journal, to represent the important research of your article on the march issue.

Thank you @CancerCell for featuring our cover! 🐝 Inspired by honeybee “social immunity” where colonies detect and manage sick nestmates, we engineered TME-regulated armored TREM2 CAR T cells to unmask and dismantle immunosuppressive niches in solid tumors @GalYagel @D_Rimini